Actively Recruiting
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
Led by M.D. Anderson Cancer Center · Updated on 2026-01-20
980
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.
CONDITIONS
Official Title
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patient 18 years old or older
- Planned treatment with an immune checkpoint inhibitor as standard care, even with additional investigational cancer treatments
- Willingness to provide informed consent
You will not qualify if you...
- Troponin T test not available at screening or before randomization
- Unable to comply with planned study procedures
- Major adverse cardiovascular event within 30 days before enrollment
- Any medical condition that could interfere with study conduct or increase risk to participant
- Factors likely to interfere with study procedures, such as history of missing scheduled appointments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
N
Nicolas Palaskas, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here